<p>Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Emtriva (Emtricitabine) Oral Capsules" href="#reference-L9019">6</a></sup> or combined with <a href="https://go.drugbank.com/drugs/DB09299">tenofovir alafenamide</a> for the prevention of HIV-1 infection in high risk adolescents and adults.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Press Announcements: FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic" href="#reference-L9010">5</a></sup> Emtricitabine is a cytidine analogue.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Emtriva (Emtricitabine) Oral Capsules" href="#reference-L9019">6</a></sup> The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Emtriva (Emtricitabine) Oral Capsules" href="#reference-L9019">6</a></sup></p><p>Emtricitabine was granted FDA approval on 2 July 2003.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Emtriva (Emtricitabine) Oral Capsules" href="#reference-L9019">6</a></sup></p>